A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: Prediction of drug-drug interaction between rosuvastatin and cyclosporine

Clinical Pharmacokinetics

Volumn 53, Issue 1, 2014, Pages 73-87

  Jamei, M ^a   Bajot, F ^a,c   Neuhoff, S ^a   Barter, Z ^a   Yang, J ^a,d   Rostami Hodjegan, A ^a,b   Rowland Yeo, K ^a  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c British American Tobacco ^*  (United Kingdom)

^d Clinical Pharmacology Modelling and Simulation GSK R and D   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN; ORGANIC ANION TRANSPORTER B; ROSUVASTATIN; SODIUM BILE ACID COTRANSPORTER; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3;

ARTICLE; CELL MEMBRANE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RESPONSE; EXTRACELLULAR FLUID; HUMAN; HUMAN CELL; IN VITRO IN VIVO EXTRAPOLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER MEMBRANE; MAXIMUM PLASMA CONCENTRATION; MICHAELIS MENTEN KINETICS; PARTITION COEFFICIENT; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CACO-2 CELLS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIMIDINES; SULFONAMIDES; YOUNG ADULT;

EID: 84891867228     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0097-y     Document Type: Article

References (86)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
2. Huang SM, Zhang L, Giacomini KM. The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther. 2010;87(1):32-6.
3. Committee for Human Medicinal Products. Guideline on the investigation of drug interactions. European Medicines Agency; 2012. http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf. Accessed 1 Apr 2013.
4. Food and Drug Administration. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (draft). U.S. Department of Health and Human Services; 2012. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf. Accessed 1 Apr 2013.
5. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007;8(7):787-802. (Pubitemid 47288978)
6. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. 2011;26(3):220-7.
7. Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584-98.
8. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 2003;25(10):2553-63. (Pubitemid 37373930)
9. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42(9):963-70. (Pubitemid 34920793)
10. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457-81. (Pubitemid 37203702)
11. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30(11):1280-7. (Pubitemid 35265837)
12. McCormick A, McKillop D, Butters C. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. Twenty Ninth Annual Meeting, American College of Clinical Pharmacology, September 17-19 Chicago, A46. J Clin Pharmacol. 2000;40:1055.
13. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54(5):472-7. (Pubitemid 35356872)
14. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78(4):330-41. (Pubitemid 41393668)
15. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci. 2006;29(3-4):205-14. (Pubitemid 44602407)
16. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, et al. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos. 2009;37(12):2349-58.
17. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36(10):2014-23.
18. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793-806.
19. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos. 2006;34(5):738-42.
20. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75(5):455-63. (Pubitemid 38534566)
21. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76(2):167-77. (Pubitemid 39013406)
22. Gibson GG, Rostami-Hodjegan A. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica. 2007;37(10-11):1013-4.
23. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50-61.
24. ® population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009;5(2):211-23.
25. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225-37.
26. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab. 2010;11(9):716-29.
27. Harwood MD, Neuhoff S, Carlson GL, Warhurst G, Rostami-Hodjegan A. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos. 2012;34(1):2-28.
28. Gibaldi M. Pharmacokinetic aspects of drug metabolism. Ann N Y Acad Sci. 1971;179(1):19-31.
29. Berezhkovskiy LM. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood-tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci. 2009;99(1):475-85.
30. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259-76. (Pubitemid 40904190)
31. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129-56. (Pubitemid 34074473)
32. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci. 2002;91(5):1358-70. (Pubitemid 34651198)
33. Rodgers T, Leahy D, Rowland M. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci. 2005;94(6):1237-48. (Pubitemid 40904188)
34. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238-57. (Pubitemid 43874439)
35. Brauer RW. Liver circulation and function. Physiol Rev. 1963;43:115-213.
36. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33-45. (Pubitemid 46043890)
37. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11(12):1481-93. (Pubitemid 43072624)
38. Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab. 2009;10(4):420-32.
39. Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically-based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010;39(5):298-309.
40. Rowland Yeo K, Jamei M, Rostami-Hodjegan A. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol. 2013;6(2):143-57.
41. Rostami-Hodjegan A, Tucker GT. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Technol. 2004;1(4):441-8. (Pubitemid 40186348)
42. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004;2:8. (Pubitemid 39111870)
43. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, et al. Mechanistic pharmacokinetic modelling for the prediction of transporter-mediated disposition in human from sandwich culture human hepatocyte data. Drug Metab Dispos. 2012;40(5):1007-17.
44. Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, et al. (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2, 4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3- methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J Med Chem. 2008;51(9):2722-33. (Pubitemid 351620794)
45. Avdeef A. Absorption and drug development. 2nd ed. Hoboken: Wiley-Interscience; 2012.
46. Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011;39(7):1196-202.
47. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726-33. (Pubitemid 350114817)
48. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol. 2009;68(2):207-13.
49. Abe K, Bridges AS, Brouwer KL. Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. Drug Metab Dispos. 2009;37(3):447-52.
50. Bergman E, Matsson EM, Hedeland M, Bondesson U, Knutson L, Lennernas H. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol. 2010;50(9):1039-49.
51. Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, et al. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos. 2011;39(9):1503-10.
52. Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos. 2008;36(12):2405-9.
53. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25(11):2822-35. (Pubitemid 37510592)
54. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25(8):2215-24. (Pubitemid 37076314)
55. Clarke J, Generaux G, Harmon K, Kenworthy KE, Polli JW. Predicting clinical rosuvastatin interactions using in-vitro OATP inhibition data. Drug Transporters in ADME: From Bench to Bedside, AAPS Transporters Workshop, 14-16 Mar 2011, Bethesda.
56. Clarke J. The use of in-vitro BCRP/OATP data to predict rosuvastatin DDI: a static modelling approach. 3rd International clinically relevant drug transporters, 28-29 Feb 2012, Berlin.
57. Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos. 2010;38(9):1499-504.
58. Varma M, Lai Y, Feng B, Litchfield J, Goosen T, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res. 2012;29(10):2860-73.
59. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol. 2013;9(4):459-72.
60. Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. J Pharm Pharmacol. 1987;39(8):599-603. (Pubitemid 17116303)
61. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem. 1993;36(24):3757-64. (Pubitemid 24006703)
62. Cefalu WT, Pardridge WM. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. J Neurochem. 1985;45(6):1954-6. (Pubitemid 16204327)
63. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003;20(5):749-56. (Pubitemid 36515307)
64. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57(5):485-91.
65. Tsunoda SM, Harris RZ, Christians U, Velez RL, Freeman RB, Benet LZ, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther. 2001;70(5):462-7. (Pubitemid 33135326)
66. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000;68(5):478-86.
67. Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther. 1998;287(2):457-68. (Pubitemid 29133641)
68. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2003;73(4):322-9. (Pubitemid 36403592)
69. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2003;59(1):51-6. (Pubitemid 36702759)
70. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002;58(8):527-31. (Pubitemid 35435506)
71. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652-62.
72. Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn. 2010;37(6):575-90.
73. Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model. 2009;6:2.
74. Poirier A, Funk C, Scherrmann J-M, Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol Pharma. 2009;6(6):1716-33.
75. Poirier A, Cascais A-C, Funk C, Lavé T. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009;36(6):585-611.
76. Menochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 2012;341(1):2-15.
77. Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, et al. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res. 2013;30(3):761-80.
78. Baker M, Parton T. Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica. 2007;37(10-11):1110-34. (Pubitemid 350035537)
79. Poirier A, Lave T, Portmann R, Brun M-E, Senner F, Kansy M, et al. Design, data analysis and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab Dispos. 2008;36(12):2434-44.
80. Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos. 2008;36(7):1365-74. (Pubitemid 351929321)
81. Shirasaka Y, Mori T, Shichiri M, Nakanishi T, Tamai I. Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites. Drug Metab Pharmacokinet. 2012;27(3):360-4.
82. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, et al. ITC recommendations on transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther. 2013;94:64-79.
83. Varma MS, Lai Y, Kimoto E, Goosen T, El-Kattan A, Kumar V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30(4):1188-99.
84. Varma MVS, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam J, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos. 2013;41(5):966-74.
85. Yoshida K, Maeda K, Sugiyama Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu Rev Pharmacol Toxicol. 2013;53(1):581-612.
86. Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G. Influence of purple grape juice in cyclosporine bioavailability. J Ren Nutr. 2010;20(5):309-13.